Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08 |
|
Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08 ±³À°ÁÖÁ¦ : Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) ÁÖÃÖ±â°ü : »ï¼º¼¿ïº´¿ø ´ã´çÀÚ : ¹Ú¹Ì³ª À̸ÞÀÏ : minasun.park@samsung.com ±³À°Á¾·ù : ÀÇ»çÇÐ Âü¼®¿¹»óÀÎ : 150¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 0¿ø ºñ°í
±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 08:55~09:00 °³È¸»ç ÇÔµ·ÀÏ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:00~09:10 Anatomy in glaucoma ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:10~09:20 Molecular biology in glaucoma Á¶Çö°æ(°æ»óÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:20~09:30 Pathophysiology in glaucoma ±è¿µ±¹(¼¿ïÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:30~09:40 Animal models in glaucoma ³ë½Â¼ö(Â÷ÀÇ°úÇдë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:40~09:50 Lymphatics and glaucoma ¹Úµµ¿µ(¼º±Õ°üÀÇ´ë) Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:50~10:10 Discussion ( ) ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:10~10:25 Coffee Break ( ) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:25~10:35 Myopia: How does it affect glaucoma? ±è¸¶¸£´Ù(µ¿±¹ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:35~10:45 Optic disc morphology: Does It predict the future VF defect pattern? ÇÑÁ¾Ã¶(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:45~10:55 FDT & 10-2 VF: Do they offer additional information? Á¤°æÀÎ(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:55~11:05 AngioOCT: The tips how to use AngioOCT in glaucoma clinic ¼¹ÎÈñ(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:05~11:15 ICP: The influence of CSF pressure in glaucoma ±è°íÀº(¿ï»êÀÇ´ë) Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:15~11:35 Discussion ( ) ±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:35~12:05 Special Session :³ì³»Àå°ú ÇÔ²²ÇÑ 30¿©³â ±ââ¿ø(¼º±Õ°üÀÇ´ë) ½Ä»ç 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ǪµåÄÚÆ® 12:05~13:30 LUNCH ( ) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:30~13:40 Congenital glaucoma ¼¿ï(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:40~13:50 Traumatic glaucoma ÀÌ°æ¹Î(¼¿ïÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:50~14:00 Uveitic glaucoma ÃÖÁø¾Æ(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:00~14:10 Pseudoexfoliative glaucoma ±èÁ¤¸²(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:10~14:20 Neovascular glaucoma ÀÌÁö¿õ(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:20~14:30 Malignant glaucoma ÀÌÅÂÀº(ÀüºÏÀÇ´ë) Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:30~14:50 Discussion ( ) ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:50~15:05 Coffee Break ( ) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:05~15:20 How to interpret the measured IOP in clinic when we consider the diurnal variation of IOP À¯Á¤±Ç(°í·ÁÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:20~15:35 How to determine the progression when we meet glaucoma patients with VF progression but without ONH change. ¹èÇü¿ø(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:35~15:50 Targeting IOP: What should we do when we meet persistent progression of glaucoma patients with low teen IOP? ÀÌÀºÁö(¼¿ïÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:50~16:05 Why are there many NTG patients in Asian population? Á¤Áø¿í(¼¿ïÀÇ´ë) ±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:05~16:20 Strategies for neuroprotection: Which should be the main target – ganglion cell, axon, or glial cell? ¹ÚÇý¿µ(°¡Å縯ÀÇ´ë) Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:20~16:50 Discussion ( ) ±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:50~16:55 Æóȸ»ç ( )
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|